NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
Clinical Trials
10 trialsNCT00535951 2020-12-19
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Novartis
Phase 1 Completed
NCT03982134 2019-10-04
PDR001 + Panobinostat for Melanoma and NSCLC
University of Iowa
Phase 1 Withdrawn
NCT01336842 2018-01-09
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
University of California, Davis
Phase 1 Completed
NCT00958022 2017-06-22
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
University of Pittsburgh
Phase 1 Terminated
NCT01005797 2017-03-03
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Medical University of South Carolina
Phase 1 Completed
NCT00907179 2015-07-22
Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
University of Pittsburgh
Phase 1 Terminated
NCT00738751 2015-02-04
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01160731 2014-12-31
Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Cancer Trials Ireland
Phase 1 Withdrawn
NCT01222936 2010-10-18
LBH Phase II in Small Cell Lung Cancer (SCLC)
Southern Europe New Drug Organization
Phase 2 Completed